Sunday, March 25, 2007

ACC.07 Late-Breaking Clinical Trials Scientific Session 1   
Press Conference: 10 – 11 a.m. CDT

402-5: “Prognostic Value of T-Wave Alternans in Patients with Heart Failure Due to Nonischemic Cardiomyopathy: Results of the T-Wave Alternans in Patients with Heart Failure (ALPHA) Study”
Release (PDF)

402-9: “Results of the Follow-Up Serial Infusions of Nesiritide for the Management of Patients With Heart Failure (FUSION II) Trial”
Release (PDF)

402-7: “Effects of Vasopressin Receptor Antagonism with Tolvaptan on Clinical Status, Morbidity and Mortality in Patients Hospitalized With Acute Decompensated Heart Failure: Results of the EVEREST Trial” 
Release (PDF)

402-11: “The Influence of Angiotensin Receptor Blockers and Blood Pressure Lowering on Diastolic Function in Patients with Hypertension and Diastolic Dysfunction: The VALsartan in Diastolic Dysfunction (VALIDD) Trial”
Release (PDF)

i2 Late-Breaking Clinical Trials Scientific Session 2       
Press Conference: 12 noon – 1 p.m. CDT

2405-5: “First United States Randomized Controlled Trial Utilizing Three-Dimensional Guided, Catheter-Based Delivery of Autologous Skeletal Myoblasts for Ischemic Cardiomyopathy: Feasibility, Safety and Improvement in Cardiac Performance”
Release (PDF)

2405-9: “Randomized Comparison of the Effect of Distal Protection and Drug Eluting Stent Versus Bare Metal Stent Implantation During Percutaneous Coronary Intervention for ST-Elevation Myocardial Infarction (DEDICATION)”
Release (PDF)

2405-7: “Targeted Inhibition of δ-Protein Kinase C to Ameliorate Reperfusion Injury During Primary Percutaneous Coronary Intervention for Acute ST-Elevation Myocardial Infarction: Results from the DELTA MI Trial”
Release (PDF)

2405-3: “A Double-Blind, Randomized, Placebo Controlled Clinical Trial of Allogeneic Mesenchymal Stem Cells for the Treatment of Patients With Acute Myocardial Infarction”
Release (PDF)

ACC.07 Smaller Late-Breaking Clinical Trials I    
No Press Conference

Press Release (##404-7, ##404-9)  (PDF)

Press Release (##404-5, ##404-6, ##404-8)  (PDF)


404-4: “Efficacy and Safety of a Potent New PPAR-Alpha Agonist as Monotherapy or in Combination With Statins in Subjects With Dyslipidemia”
Release (PDF)

 i2 Late-Breaking Emerging Technologies and Innovations Scientific Sessions     
No Press Conference

Press Release (##2406-3, ##2406-5, ##2406-7)  (PDF)  

Press Release (##2406-9, ##2406-11, ##2406-13) (PDF)

 

Click Here to View Press Releases from Saturday, March 24th.

For More Information:
Amy Murphy
Senior Specialist, Media Relations
(202) 375-6476
amurphy@acc.org


All abstracts are embargoed until their presentation time or an official ACC.07/i2 Summit press conference, whichever occurs first. General abstracts will be published in the March 6, 2007 issue of the Journal of the American College of Cardiology (JACC).

 

 

American College of Cardiology ACC.07 and i2 Summit Press Conference Schedule

American College of Cardiology ACC.07 and i2 Summit Conference Schedule Calendar

 

American College of Cardiology Confirms New Orleans for 2007 Scientific Session

(BETHESDA, MD) The American College of Cardiology (ACC) has confirmed that it will hold its 56th Annual Scientific Session in New Orleans on March 24 – 27, 2007.   The scientific session will include the second annual Innovation in Intervention: i2 Summit.

“We are delighted to reconfirm our commitment to New Orleans as the host city for our  annual scientific meeting,” said Pamela. S. Douglas, M.D., F.A.C.C., president of the ACC.  “New Orleans has always been a great venue for the world’s most prestigious cardiovascular scientific meeting, and we are confident that 2007 will be another great experience.”

Following hurricanes Katrina and Rita, the ACC volunteer and staff leadership began a thorough examination of the city’s viability to host the Scientific Session and its anticipated 30,000 attendees.  ACC staff members toured the area and confirmed that the ACC meeting activities and requisite hotels were located in areas that escaped flooding — the central Business District and the French Quarter.

Many restaurants, shops and hotels are already back in business, and essential services have been fully restored.  “We realize that many sections of the city have suffered tremendous damage, and we hope that by reaffirming our commitment to the city, we can lead by example, providing resources that are vital to the city’s overall rebuilding effort,” added Douglas.

New Orleans has committed to providing a flawless experience that will meet ACC members’ highest standards. The ACC is confident that the city will be prepared to welcome its Annual Scientific Session, ACC.07, and Innovation in Intervention: i2 Summit in 2007.

The American College of Cardiology is leading the way to optimal cardiovascular care and disease prevention. The College is a 33,000-member nonprofit medical society and bestows the credential Fellow of the American College of Cardiology upon physicians who meet its stringent qualifications. The College is a leader in the formulation of health policy, standards and guidelines, and is a staunch supporter of cardiovascular research. The ACC provides professional education and operates national registries for the measurement and improvement of quality care.